血清FT<sub>3</sub>、FT<sub>4</sub>水平对甲亢患者并发甲亢性心脏病的评估价值

doi:10.3969/j.issn.1671-7171.2024.03.013

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1186 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨血清游离三碘甲腺原氨酸(FT₃)、游离甲状腺素(FT₄)对甲状腺功能亢进(简称甲亢)患者并发甲亢性心脏病的评估价值。【方法】选取2021年1月至2023年1月西安市长安区医院收治84例的甲亢患者,依据甲亢患者是否并发甲亢性心脏病分为并发组(n=10)和未并发组(n=74)。比较两组患者临床资料;采用Logistic多因素回归分析甲亢患者并发甲亢性心脏病的影响因素;采用受试者工作特征(ROC)曲线分析FT₃、FT₄及两者联合检测对甲亢患者并发甲亢性心脏病的评估效能。【结果】甲亢患者并发甲亢性心脏病发生率为11.90%(10/84)。两组性别、年龄、合并糖尿病、吸烟史、使用甲亢药物、尿酸、甘油三酯、血红蛋白、白蛋白、合并感染占比比较,差异均无统计学意义(P>0.05);并发组FT₃、FT₄水平均高于未并发组(P<0.05)。多因素分析结果显示:FT₃、FT₄均是甲亢患者并发甲亢性心脏病的影响因素(OR=3.256、3.368,P<0.05)。FT₃、FT₄预测甲亢患者并发甲亢性心脏病的最佳截断值分别为10.25 pmol/L、36.52 pmol/L,曲线下面积(AUC)分别为0.785、0.756,两者联合评估的特异度为92.69%,高于FT₃、FT₄单独进行评估的特异度(P<0.05)。【结论】甲亢患者并发甲亢性心脏病发生率较高,FT₃、FT₄对甲亢患者并发甲亢性心脏病具有一定的评估价值,且两者联合评估价值更高,可作为临床评估甲亢患者并发甲亢性心脏病的重要参考指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李丹
	黄峰

关键词 ：甲状腺功能亢进症/并发症, 心脏病/病因学, 三碘甲状腺原氨酸/血液, 甲状腺素/血液

Abstract：【Objective】To explore the evaluation value of serum free triiodothyronine(FT₃) and free thyroxine(FT₄) in patients with hyperthyroidism complicated with hyperthyroid heart disease. 【Methods】A total of 84 patients with hyperthyroidism treated in Chang'an District Hospital from January 2021 to January 2023 were selected in the study. The incidence of hyperthyroidism patients complicated with hyperthyroidism heart disease was counted, and patients were divided into concurrent group(10 cases) and non-concurrent group(74 cases) according to whether hyperthyroidism heart disease occurred. The clinical data of patients in concurrent group and non-concurrent group were compared. Multivariate logistic regression analysis was used to analyze the risk factors of hyperthyroidism patients complicated with hyperthyroidism heart disease. The efficacy of FT₃ and FT₄ in the evaluation of hyperthyroidism patients complicated with hyperthyroidism heart disease was analyzed. 【Results】There were 10 cases of hyperthyroid patients complicated with hyperthyroid heart disease, which showed that the incidence of hyperthyroid heart disease was 11.90%. There were no significant differences in gender, age, diabetes mellitus, smoking history, hyperthyroidism drug use, uric acid, triglyceride, hemoglobin, albumin and infection between the concurrent group and the non-concurrent group(P>0.05). FT₃ and FT₄ in the concurrent group were higher than those in the non-concurrent group(P<0.05). The results of multivariate analysis showed that both FT₃ and FT₄ were independent risk factors for hyperthyroid patients complicated with hyperthyroid heart disease(OR=3.256, 3.368, P<0.05). The best cutoff points of FT₃ and FT₄ in predicting hyperthyroidism complicated with hyperthyroidism heart disease were 10.25 pmol/L and 36.52 pmol/L respectively, and the area under the curve(AUC) was 0.785 and 0.756. The specificity of the combination of FT₃ and FT₄ was 92.69%, which was higher than that of FT₃ and FT₄ alone(P<0.05). 【Conclusion】The incidence of hyperthyroid patients complicated with hyperthyroid heart disease is high. FT₃ and FT₄ have certain value in the evaluation of hyperthyroid patients complicated with hyperthyroid heart disease, but the value of their combined detection is even higher, which can be used as an important reference index for clinical evaluation.

Key words： Hyperthyroidism/CO Heart Diseases/ET Triiodothyronine/BL Thyroxine/BL

收稿日期: 2023-04-25

中图分类号:

R581.1

通讯作者: *E-mail:867543952@qq.com

引用本文:

李丹, 黄峰. 血清FT₃、FT₄水平对甲亢患者并发甲亢性心脏病的评估价值[J]. 医学临床研究, 2024, 41(3): 368-370.
LI Dan, HUANG Feng. Evaluation Value of FT₃ and FT₄ Levels in Patients with Hyperthyroidism Complicated with Hyperthyroid Heart Disease. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 368-370.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.03.013 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I3/368

[1] 李斌义,葛洪波,王波,等. 超声斑点追踪技术联合心肌肌钙蛋白T与有效甲状腺素比值在甲亢性心脏病中的联合诊断价值[J].中国超声医学杂志,2021,37(9):998-1001.
[2] 孙加凤,张丽,彭兴,等. 血清NT-proBNP、ALCAT1与25(OH)D联合检测在老年甲亢性心脏病患者诊断中的应用价值[J].老年医学与保健,2021,27(3):598-601.
[3] 郑晓红,孙立娟,史红珍,等. 放射性碘联合丹参注射液对甲亢性心脏病患者FT₃、TSH、TRAb及心功能指标的影响[J].中国地方病防治杂志,2019,34(4):437-439.
[4] 韩晨鹏,徐清芳,张美华. 糖尿病甲亢性心脏病患者血浆NT-proBNP水平与心脏功能的关系研究[J].首都食品与医药,2019,26(5):88.
[5] 朱清华. NT-proBNP检测在甲亢性心脏病早期诊断中的应用价值[J].中外医疗,2019,37(34):190-192.
[6] 何源,刘青. 甲亢性心脏病患者血浆NT-proBNP水平与左室功能关系的研究[J].大连医科大学学报,2019,39(4):387-389.
[7] 葛均波, 徐永健. 内科学[M].8版. 北京:人民卫生出版社, 2013:5.
[8] LI H,ZENG R L,LIAO Y F,et al. Association of plasma connective tissue growth factor levels with hyperthyroid heart disease[J].Curr Med Sci,2021,41(2):348-355.
[9] HOU R ,JIN X S ,GAO Y H ,et al. Evaluation of the effects of schisandra chinensis on the myocardium of rats with hyperthyroid heart disease by using velocity vector imaging combined with the estimation of p53 expression and calmodulin activity[J].Evid Based Complement Alternat Med,2020,33(1):110-126.
[10] SHAN D,BAI Y,CHEN Q H,et al. Hyperthyroid heart disease in pregnancy:retrospective analysis of a case series and review of the literature[J].World J Clin Cases,2019,7(19):2953-2962.
[11] ZHANG X J,CHEN L,SHENG J P,et al. The association of autoantibodies in hyperthyroid heart disease combined with pulmonary hypertension[J].Int J Endocrinol,2020,35(6):527-535.
[12] WANG Q,LI C,DI S,et al. Clinical efficacy and safety of traditional Chinese patent medicine for hyperthyroid heart disease: study protocol for a systematic review and meta-analysis[J].Medicine,2020,35(8):1353-1361.
[13] KIM H, PARK J T, LEE J, et al. The difference between cystatin C-and creatinine-based eGFR is associated with adverse cardiovascular outcome in patients with chronic kidney disease[J].Atherosclerosis,2020,335(10):53-61.
[14] SCHEIDT M J, HOHENWALTER E J, PINCHOT J W, et al. FT₃ appropriateness criteria^® radiologic maement of urinary tract obstruction[J].J Am Coll Radiol,2020,17(5S):S281-S292.
[15] WONG-YOU-CHEONG J J, NIKOLAIDIS P, KHATRI G, et al. FT₃ appropriateness criteria^® renal failure[J].J Am Coll Radiol,2020,18(5):S174-S188.